1：Experimental Design and Method Selection:

The study involved phase solubility studies to evaluate drug solubility with different cyclodextrins, characterization of inclusion complexes using DSC, FT-IR, and 1H-NMR, and formulation of eye drops with various polymers. Methods included sonication for heating, freeze-drying for sample preparation, and analytical techniques like UHPLC for quantification.

2：Sample Selection and Data Sources:

Nepafenac was used as the drug model. Cyclodextrins (αCD, βCD, γCD, HPαCD, HPβCD, HPγCD) and polymers (PVP, PVA, CMC, HPMC, MC, tyloxapol) were selected based on previous studies. Data were sourced from experimental measurements.

3：List of Experimental Equipment and Materials:

Equipment included moisture analyser, sonicator, UHPLC system, FT-IR spectrometer, DSC instrument, 1H-NMR spectrometer, centrifuge, particle size analyser, viscometer, osmometer, and TEM. Materials included nepafenac, cyclodextrins, polymers, solvents, and chemicals of analytical grade.

4：Experimental Procedures and Operational Workflow:

Procedures involved moisture content measurement, chemical stability tests, phase solubility studies with sonication and shaking, complex preparation by freeze-drying, spectroscopic analyses, formulation of eye drops with specific compositions, and characterization of formulations for solubility, viscosity, osmolality, and particle size.

5：Data Analysis Methods:

Data were analyzed using software like Chromeleon for HPLC, with calculations for stability constants and complexation efficiency. Statistical analysis included mean and standard deviation from triplicate measurements.